Table 4.

Percentage agreement for indicated use of individual immunosuppressive drugs in compared data sources^a

Drug	OPTN/MR	±30 D of Follow-up Date Window for Ascertainment		±90 D of Follow-up Date Window for Ascertainment
		OPTN/CLM	MR/CLM	OPTN/CLM	MR/CLM
Cyclosporine
discharge	92.7	93.8	96.0	96.9	98.0
6 mo	93.1	82.6	89.5	93.5	96.5
1 yr	94.9	96.4	97.0	98.3	100.0
Tacrolimus
discharge	95.6	96.9	100.0	96.9	100.0
6 mo	94.8	93.5	94.7	95.7	96.5
1 yr	97.8	100.0	100.0	100.0	100.0
MMF
discharge	84.7	83.1	98.0	84.6	100.0
6 mo	91.4	89.1	84.2	91.3	87.7
1 yr	95.7	91.1	94.0	92.9	95.5
Azathioprine
discharge	81.0	69.2	92.0	75.4	96.0
6 mo	92.2	91.3	87.7	93.5	96.5
1 yr	92.8	87.5	90.9	92.9	95.5
Sirolimus
discharge	99.3	100.0	100.0	100.0	100.0
6 mo	100.0	100.0	100.0	100.0	100.0
1 yr	100.0	100.0	100.0	100.0	100.0
Prednisone
discharge	97.8	83.1	80.0	97.8	86.0
6 mo	98.3	60.9	54.4	73.9	71.9
1 yr	98.6	57.4	54.6	66.1	68.2

^aAnalytic samples were defined by the availability of maintenance immunosuppression information in the data sources under comparison at the study time points of interest. Percentage agreement indicates the proportion of the analytic sample that has been similarly classified by both sources.